Healthy Skepticism Library item: 14946

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: media release

Loukas E.
Sales Through Retail Pharmacies (Twelve months to November 2008*)
IMS 2009
http://view.respond.imshealth.com/?j=fe8a12757c66067471&m=fef31377726304&ls=fdf51577706d027d77137070&l=fe9c1570746204787

Full text:

NORTH AMERICA $225.5 billion up 2%
U.S.A. $208.7 billion up 1%
CANADA $16.8 billion up 6%

EUROPE (TOP 5) $114.6 billion up 1%
GERMANY $35.2 billion up 4%
FRANCE $30.7 billion up 0%
UK $16.0 billion down 2%
ITALY $17.2 billion up 1%
SPAIN $15.3 billion up 4%

JAPAN (including hospitals) $66.7 billion up 2%

LATIN AMERICA (TOP 3) $24.4 billion up 9%
BRAZIL $12.5 billion up 11%
MEXICO $8.6 billion up 2%
ARGENTINA $3.2 billion up 22%

AUSTRALIA/NZ $7.9 billion up 10%

The top 5 therapy classes at ATC3 level in the 12 months to November 2008 were:

1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics

The top 5 products in the 12 months to November 2008 were:

1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel

The top 5 corporations in the 12 months to November 2008 were:

1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis